Automated online monitoring & control to improve processes and decision making in cell and gene therapy manufacturing
The project aims to develop an automated, self-contained bioreactor with continuous monitoring of critical process parameters to enhance scalability and quality in cell and gene therapy manufacturing.
Projectdetails
Problem
Cell and gene therapies (CGT) represent a breakthrough in the treatment of a wide range of conditions. However, limited global manufacturing capacity owing to a lack of scalability prevents CGT from becoming widely available to patients. Therapies are prepared individually at central facilities in a series of complex open manual steps.
Variability is high, and a uniform manufacturing process is lacking. Automated, standardized, quality-controlled, and decentralized processes are urgently needed to scale out CGT manufacturing, bring down costs, and enable treatment for millions of patients. True automation requires an understanding of what are known as critical process parameters (CPPs). Currently, manufacturing of cell therapies is carried out over several days, with limited access to knowledge of CPPs, often obtained through intrusive sampling methods.
Innovation
We aim to enable in-line continuous monitoring of key cell culture parameters during therapy manufacturing. To do this, we will create a self-contained instrument that connects miniaturized biosensor technologies to a novel bioreactor to allow automation of the entire cell therapy manufacturing process in a closed system.
The device will accommodate a disposable, single-use sampling unit that will ultimately be adaptable to any bioreactor. Our platform will carry out continuous, automated, and closed monitoring of a set of well-defined CPPs, as indicators of the overall state of the cell culture.
We will select and refine our parameters and establish optimal ranges, as predictors of process outcomes and product quality, based on prediction algorithms and digital twin analysis. This will allow continuous process monitoring while greatly lowering costs and risks associated with manual sampling.
Our first application will be in CAR T cell therapy production, but the advantages of automation with continuous monitoring will be further applied to other CGT products that involve culturing of cells.
Financiële details & Tijdlijn
Financiële details
Subsidiebedrag | € 3.617.783 |
Totale projectbegroting | € 3.617.783 |
Tijdlijn
Startdatum | 1-10-2022 |
Einddatum | 30-9-2025 |
Subsidiejaar | 2022 |
Partners & Locaties
Projectpartners
- DA VINCI LABSpenvoerder
- JOBST TECHNOLOGIES GMBH
- STEMMATTERS, BIOTECNOLOGIA E MEDICIINA REGENERATIVA SA
- TECHNISCHE UNIVERSITAET WIEN
- EXOTHERA SA
- CROWDHELIX LIMITED
- LIMULA SA
Land(en)
Vergelijkbare projecten binnen EIC Pathfinder
Project | Regeling | Bedrag | Jaar | Actie |
---|---|---|---|---|
Smart manufacturing for autologous cell therapies enabled by innovative biomonitoring technologies and advanced process controlThe SMARTER project aims to develop a smart bioprocessing platform for personalized autologous cell therapies, enhancing manufacturing efficiency and enabling clinical use for solid tumors. | EIC Pathfinder | € 1.364.281 | 2022 | Details |
NOn-VIral gene modified STEM cell therapyThis project aims to develop a high-throughput protocol for producing gene-corrected CAR T cells and blood stem cells using optimized photoporation and CRISPR technology for enhanced clinical application. | EIC Pathfinder | € 3.644.418 | 2022 | Details |
AI-powered platform for autologous iPSC manufacturingThe project aims to develop an AI-guided microfluidic device for the standardized, cost-effective mass production of personalized iPSCs to enhance cancer therapies and tissue regeneration. | EIC Pathfinder | € 3.999.225 | 2022 | Details |
FINE-TUNING T CELL NETWORKS OF EXHAUSTION BY SYNTHETIC SENSORST-FITNESS aims to enhance T cell therapy by preventing exhaustion through miRNA-based circuits and CRISPR/Cas editing, improving treatment efficacy for solid tumors in cancer patients. | EIC Pathfinder | € 4.387.825 | 2022 | Details |
Exploiting ex vivo expansion and deep multiomics profiling to bring novel, efficient and safer hematopoietic stem cell gene therapies to clinical applicationThis project aims to innovate hematopoietic stem cell identification and engineering through advanced culture techniques and multiomics profiling, enhancing gene therapy for blood disorders and cancer. | EIC Pathfinder | € 3.797.562 | 2022 | Details |
Smart manufacturing for autologous cell therapies enabled by innovative biomonitoring technologies and advanced process control
The SMARTER project aims to develop a smart bioprocessing platform for personalized autologous cell therapies, enhancing manufacturing efficiency and enabling clinical use for solid tumors.
NOn-VIral gene modified STEM cell therapy
This project aims to develop a high-throughput protocol for producing gene-corrected CAR T cells and blood stem cells using optimized photoporation and CRISPR technology for enhanced clinical application.
AI-powered platform for autologous iPSC manufacturing
The project aims to develop an AI-guided microfluidic device for the standardized, cost-effective mass production of personalized iPSCs to enhance cancer therapies and tissue regeneration.
FINE-TUNING T CELL NETWORKS OF EXHAUSTION BY SYNTHETIC SENSORS
T-FITNESS aims to enhance T cell therapy by preventing exhaustion through miRNA-based circuits and CRISPR/Cas editing, improving treatment efficacy for solid tumors in cancer patients.
Exploiting ex vivo expansion and deep multiomics profiling to bring novel, efficient and safer hematopoietic stem cell gene therapies to clinical application
This project aims to innovate hematopoietic stem cell identification and engineering through advanced culture techniques and multiomics profiling, enhancing gene therapy for blood disorders and cancer.
Vergelijkbare projecten uit andere regelingen
Project | Regeling | Bedrag | Jaar | Actie |
---|---|---|---|---|
Continuous Digitalized Processes for Producing BiopharmaceuticalsDeveloping a Digital Twin-based methodology for continuous, integrated biopharmaceutical production to enhance efficiency and support advanced therapies like mRNA vaccines and personalized medicine. | ERC Advanced... | € 2.500.000 | 2023 | Details |
Enabling efficient cell engineering leaving gene-expression BURden OUT for cell therapies and biopharmaceutical industryBURnOUT is an AI-driven software designed to optimize gene sequences for efficient mammalian cell engineering, aiming to reduce costs and enhance therapies for cancer and biopharmaceuticals. | ERC Proof of... | € 150.000 | 2024 | Details |
Commercial feasibility of a cell-free reactor setup for optimisation of complex enzymatic pathwaysThis project aims to commercialize a continuous stirred tank reactor for optimizing complex enzymatic pathways, enhancing production efficiency and establishing a viable commercialization strategy. | ERC Proof of... | € 150.000 | 2022 | Details |
Generation, validation and use of a synthetic reporter of CAR T cell products function and dysfunctionDevelop a synthetic reporter system to enhance T cell fitness in immunotherapy by identifying and reversing dysfunction in CAR T cells for improved cancer treatment. | ERC Proof of... | € 150.000 | 2024 | Details |
Fast and simple biomarker detection by computational microscopyWe developed a fast, sensitive biomarker detection method for early diagnosis and monitoring of cancer treatments, aiming to improve patient outcomes through preventative diagnostics. | ERC Proof of... | € 150.000 | 2024 | Details |
Continuous Digitalized Processes for Producing Biopharmaceuticals
Developing a Digital Twin-based methodology for continuous, integrated biopharmaceutical production to enhance efficiency and support advanced therapies like mRNA vaccines and personalized medicine.
Enabling efficient cell engineering leaving gene-expression BURden OUT for cell therapies and biopharmaceutical industry
BURnOUT is an AI-driven software designed to optimize gene sequences for efficient mammalian cell engineering, aiming to reduce costs and enhance therapies for cancer and biopharmaceuticals.
Commercial feasibility of a cell-free reactor setup for optimisation of complex enzymatic pathways
This project aims to commercialize a continuous stirred tank reactor for optimizing complex enzymatic pathways, enhancing production efficiency and establishing a viable commercialization strategy.
Generation, validation and use of a synthetic reporter of CAR T cell products function and dysfunction
Develop a synthetic reporter system to enhance T cell fitness in immunotherapy by identifying and reversing dysfunction in CAR T cells for improved cancer treatment.
Fast and simple biomarker detection by computational microscopy
We developed a fast, sensitive biomarker detection method for early diagnosis and monitoring of cancer treatments, aiming to improve patient outcomes through preventative diagnostics.